Alternatively, glial fibrillary acidic protein (GFAP), an intermediate filament found in astrocytes analogous to NfL in neurons, has been suggested as a biomarker for assessing current disease progression and predicting future outcomes in MS [7,8]. Here, GFAP is linked to myeloid sarcoma.